Features | Healtcare News | BioTuesdays by Kilmer Lucas IR

This Week's Feature

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Jim Joyce, co-founder, chairman and CEO Sigyn Therapeutics (OTCQB:SIGY) has transitioned its Sigyn Therapy blood-purification device from conceptual design two years ago to preparing to initiate its first-in-human...

October 4, 2022

Feature

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Brian Strem, Ph.D., President and CEO Kiora Pharmaceuticals (NASDAQ:KPRX) expects to release Phase 1b interim data at the beginning of 2023 from its flagship intravitreal injection to potentially restore vision in...

September 27, 2022

Feature

Blue Water Vaccines designing vaccines against infectious diseases

Blue Water Vaccines (NASDAQ:BWV) is building an early-stage pipeline of six transformational vaccine candidates targeting important infectious diseases, including inner ear infections, influenza, norovirus, rotavirus...

September 20, 2022

Feature

SAB Biotherapeutics advancing new class of immunotherapeutic antibodies

SAB Biotherapeutics (NASDAQ:SABS) is developing its novel DiversitAb platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies, without the need for human donors.

September 13, 2022

Feature

Ensysce Biosciences’ transformative chemistry targeting drug safety and performance

Ensysce Biosciences (NASDAQ:ENSC) is developing next-generation opioid products with its platform of two proprietary technologies to reduce abuse and overdose while relieving suffering for people with severe pain and...

September 6, 2022

Feature

Femasys innovating women’s reproductive health with minimally invasive, in-office technologies

Femasys (NASDAQ:FEMY) is on a road to disrupt traditional approaches to women’s reproductive health with proprietary diagnostics and devices that address global markets in infertility and permanent birth control.

August 30, 2022

Feature

Talking VR and mental health with Foretell Reality

As general manager for Foretell Reality and VP product for parent, Glimpse Group (NASDAQ:VRAR), a company seeking to unlock the benefits of virtual and augmented reality, Dror Goldberg was introduced to VR in its early...

August 23, 2022

Feature

Zymeworks targeting cancer with next-gen multifunctional biotherapeutics

Zymeworks (NYSE:ZYME) is leading a paradigm shift developing next-generation multifunctional antibodies and antibody drug conjugates, with an initial focus on HER2-targeted therapies to treat cancer.

August 16, 2022

Feature

Brickell Biotech pivots to make fresh tracks in autoimmune, inflammatory medicine

After selling its late-stage dermatology program in May 2022, Brickell Biotech (NASDAQ:BBI) has pivoted its focus to developing differentiated therapeutics for the treatment of autoimmune, inflammatory and other...

August 9, 2022

Feature

Rhythm Pharma targeting rare genetic diseases of obesity

Rhythm Pharmaceuticals (NASDAQ:RYTM), with the only FDA-approved therapy that targets a root cause of severe obesity and insatiable hunger, is in clinical development to expand the addressable population of patients...

August 2, 2022

Feature

Eupraxia Pharmaceutical’s novel release technology aims to improve lives of knee OA sufferers

Eupraxia Pharmaceuticals (TSX:EPRX) is developing a unique diffusion-based polymer-particle technology initially to provide knee osteoarthritis (OA) patients with an injection in the knee for an extended release of drug...

July 26, 2022

Feature

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

Tonix Pharmaceuticals (NASDAQ:TNXP) is engaged in a number of ongoing and planned clinical trials with a rich pipeline of products, including a Phase 3 clinical trial to treat fibromyalgia, along with a Phase 2 clinical...

July 19, 2022

Feature

TC Biopharm developing gamma-delta T-cells therapies for oncology

TC BioPharm (NASDAQ:TCBP) is a global leader in developing platform allogeneic gamma-delta T-cell therapies for cancer indications, with human efficacy data in acute myeloid leukemia (AML) and plans to expand into other...

July 12, 2022

Feature

Aristea Therapeutics in four clinical trials in rare inflammatory diseases

Closely-held Aristea Therapeutics is pursuing four rare inflammatory diseases with its oral, once-daily, small molecule drug candidate, RIST4721: palmoplantar pustulosis, familial Mediterranean fever, Behcet’s disease...

July 5, 2022

Feature

Pharvaris providing patient choice in developing oral treatments for hereditary angioedema

Pharvaris (NASDAQ:PHVS), a trans-Atlantic company, is developing two oral products to treat and prevent attacks in all subtypes of hereditary angioedema (HAE), with on-demand and prophylactic therapies.

June 28, 2022

Feature

NeuroSense advancing potential paradigm shift in ALS therapy

NeuroSense Therapeutics (NASDAQ:NRSN) is developing a novel fixed dose combination of two FDA-approved drugs for a multi-targeted approach against the potential pathways responsible for ALS, or amyotrophic lateral...

June 21, 2022

Feature

QSAM Biosciences developing next-gen targeted radiopharmaceuticals for cancer

QSAM Biosciences (OTCQB:QSAM) began dosing bone cancer patients in a Phase 1 study in April 2022 with its next-generation radiopharmaceutical, CycloSam, which delivers the beta-emitting radioisotope, samarium-153, to...

June 14, 2022

Feature

Synlogic advancing novel biotherapeutics based on synthetic biology

Synlogic (NASDAQ:SYBX) is advancing a new class of biotherapeutics, known as Synthetic Biotics, targeting validated biology in rare metabolic and immunological diseases.

June 7, 2022

Feature

Iterion Therapeutics addressing multiple cancers with TBL1 inhibition

Closely-held Iterion Therapeutics is employing a unique strategy with its lead asset, tegavivint, which is designed to bind to TBL1 (transducin beta-like protein one) and inhibit nuclear beta-catenin signaling and...

May 31, 2022

Feature

MindMed driving therapeutic potential of psychedelics for brain health disorders

MindMed (NASDAQ:MNMD; NEO:MMED) is advancing a pipeline of psychedelic and next generation drug candidates to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology.

May 24, 2022

Feature

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

Closely-held Lanier Biotherapeutics is pioneering a first-in-class Type 2 and non- Type2 anti-inflammatory biologic, LNR 125, as a new candidate targeting treatments commonly associated with Type 2 inflammation like...

May 17, 2022

Feature

Qualigen advancing platform technologies in therapeutics and diagnostics

Backed by a commercial diagnostics business, Qualigen Therapeutics (NASDAQ:QLGN) has broadened its focus to developing platform therapeutics for cancer with potential orphan drug designation.

May 10, 2022

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Blue Water Vaccines designing vaccines against infectious diseases

SAB Biotherapeutics advancing new class of immunotherapeutic antibodies

Ensysce Biosciences’ transformative chemistry targeting drug safety and performance

Femasys innovating women’s reproductive health with minimally invasive, in-office technologies

Talking VR and mental health with Foretell Reality

Zymeworks targeting cancer with next-gen multifunctional biotherapeutics

Brickell Biotech pivots to make fresh tracks in autoimmune, inflammatory medicine

Rhythm Pharma targeting rare genetic diseases of obesity

Eupraxia Pharmaceutical’s novel release technology aims to improve lives of knee OA sufferers

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

TC Biopharm developing gamma-delta T-cells therapies for oncology

Aristea Therapeutics in four clinical trials in rare inflammatory diseases

Pharvaris providing patient choice in developing oral treatments for hereditary angioedema

NeuroSense advancing potential paradigm shift in ALS therapy

QSAM Biosciences developing next-gen targeted radiopharmaceuticals for cancer

Synlogic advancing novel biotherapeutics based on synthetic biology

Iterion Therapeutics addressing multiple cancers with TBL1 inhibition

MindMed driving therapeutic potential of psychedelics for brain health disorders

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

Qualigen advancing platform technologies in therapeutics and diagnostics

General

More